论文部分内容阅读
目的：探讨帕利哌酮缓释片联合艾司西酞普兰治疗残留型精神分裂症的临床疗效及安全性。方法将80例残留型精神分裂症患者随机分为两组，每组40例。两组均晨口服帕利哌酮缓释片治疗，实验组在此基础上联合艾司西酞普兰治疗。观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗第8周末，实验组总有效率为92．5％，对照组为70．0％，实验组显著高于对照组（P＜0．01）；治疗后两组阳性与阴性症状量表总分及阳性症状、阴性症状因子分均较治疗前显著降低（P ＜0．01），研究组显著低于对照组（P＜0．01）。结论帕利哌酮缓释片联合艾司西酞普兰治疗残留型精神分裂症疗效显著，优于单用帕利哌酮缓释片治疗，安全性高。“,”Objective To explore the efficacy and safety of paliperidone extended‐release tablets (paliperi‐done ER) combined with escitalopram in residual schizophrenia (RS) .Methods Eighty RS patients were randomly divided into two groups of 40 ones each .Both groups took orally paliperidone ER in the morn‐ing ,on this basis experimental group was plus escitalopram for 8 weeks .Before and after treatment effica‐cies were assessed using the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week the total effective rate was respectively 92 .5% in experimental and 70 .0% in control group ,the former significantly higher than the latter (P< 0 .01) ;after treatment the total ,positive and negative symptom scores of both groups lowered more significantly compared with pretreatment (P < 0 .01) ,so did those in experimental than in control group (P< 0 .01) .Conclusion Paliperidone ER plus escitalopram have an evident effect and higher safety compared with single paliperidone ER in residual schizophrenia .